A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma

Summary

This is an open-label, single arm, multi-center Phase 2 study of oral Rocbrutinib in patients with mantle cell lymphoma who are failed or relapsed after remission or intolerated to Bruton's tyrosine kinase (BTK) inhibitor.

Timeline

Start

2023-02-21

Primary completion

2024-12-05

Completion

2026-06-30

Drugs

Indications